alexa Reply to Letter to the Editor | OMICS International
ISSN: 2329-9517
Journal of Cardiovascular Diseases & Diagnosis
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Reply to Letter to the Editor

Peter A McCullough*
Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, The Heart Hospital, Plano, USA
Corresponding Author : Peter A McCullough
Baylor Heart and Vascular Institute, 621 N. Hall St., #H030
Dallas, TX 75226, USA
Tel: (214) 820-7500 (O),(214) 820-7997
E-mail: [email protected] baylorhealth.edu
Received March 07, 2016; Accepted March 09, 2016; Published March 13, 2016
Citation: McCullough PA (2016) Reply to Letter to the Editor. J Cardiovasc Dis Diagn 4: e101. doi:10.4172/2329-9517.1000e101
Copyright: © 2016 McCullough PA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cardiovascular Diseases & Diagnosis

Patiromer Sorbitex Calcium: Author Response
We respect the comments in the letter to the editor concerning mention of the novel product patiromer sorbitex calcium for the treatment of hyperkalemia. The authors point out that at the minimum dose of patiromer, 8.4 g, patients will receive 1600 mg of calcium while at the minimum dose of sodium zirconium cyclosilicate 5 g, patients will receive ~400 mg of sodium as the counter exchange ion. The package insert for this product recently released in the United States indicates: “The active ingredient is patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassiumbinding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 g of patiromer sorbitex calcium.” Accordingly the Medication Guide for patients states: “The most common side effects of Veltassa include: constipation, diarrhea, nausea, stomach-area (abdominal) discomfort, and gas [1].” The per capita daily consumption of sorbitol as a food additive is 200 mg [2]. The threshold for sorbitol to induce diarrhea is ~20 g. Thus in our view some of the gastrointestinal side effects could conceivably be related to the sorbitol component of the product. The placebocontrolled study in patients with chronic heart failure (the PEARL-HF) trial tested RLY5016 30 g per day total dose which is higher than the maximum 25.2 g per day of patiromer sorbitex calcium recommended in the package insert [3]. The rates of gastrointestinal adverse events were 21% with 30 g of RLY5016 and 6% with placebo. Inferences on how lower doses of commercially available patiromer sorbitex calcium would perform in the same population are limited.
References

 

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 24th Annual CardiologistsConference
    June 11-13, 2018 Barcelona, Spain
  • 3rd International Conference on Cardiovascular Medicine and Cardiac Surgery
    July 05-06, 2018 Berlin, Germany
  • 24th World CardiologyConference
    September,17-18, 2018, Hong Kong

Article Usage

  • Total views: 8092
  • [From(publication date):
    March-2016 - May 20, 2018]
  • Breakdown by view type
  • HTML page views : 7981
  • PDF downloads : 111
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

chemistry[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7